Xellsmart Bio-pharmaceutical (suzhou) Co., Ltd.
Clinical trials sponsored by Xellsmart Bio-pharmaceutical (suzhou) Co., Ltd., explained in plain language.
-
Stem cell injection aims to replace lost brain cells in Parkinson's
Disease control Recruiting nowThis study tests a single injection of lab-grown nerve cells made from stem cells to treat early-onset Parkinson's disease. The cells are designed to replace the dopamine-producing neurons that are lost in Parkinson's. The trial has two phases: first, a small safety test in 6-12 …
Phase: PHASE1, PHASE2 • Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Stem cells injected into spine: hope for paralysis?
Disease control Recruiting nowThis early-stage study tests a new treatment called XS228, made from special stem cells that can become nerve cells. The goal is to see if injecting these cells into the spine is safe and tolerable for people who had a spinal cord injury 2 to 8 weeks ago. Up to 12 adults with inj…
Phase: PHASE1 • Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Stem cells injected into ALS patients in first human trial
Disease control Recruiting nowThis early-stage trial tests whether injecting lab-grown nerve cells (made from stem cells) into the spinal cord is safe for people with ALS, a fatal disease that destroys movement control. Twelve participants will receive the cells either once or four times over six months. The …
Phase: PHASE1 • Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Brain cell transplant trial aims to restore movement in Parkinson's
Disease control Recruiting nowThis early-stage trial tests a single injection of lab-grown nerve cells into the brains of 12 people with Parkinson's disease. The cells are made from stem cells and designed to replace dopamine-producing neurons. The main goal is to check safety and tolerability over 28 days, n…
Phase: PHASE1 • Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:48 UTC